Interleukin-8 serum levels at fever onset in patients with neutropenia predict early medical complications

Infection

Volumn 33, Issue 5-6, 2005, Pages 380-382

  Engel, A ^a   Knoll, S A ^a   Kern, P ^b   Kern, W V ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 8;

ADULT; AGED; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DISEASE MARKER; DISEASE SEVERITY; FATALITY; FEBRILE NEUTROPENIA; FEVER; GRAM NEGATIVE SEPSIS; HUMAN; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; PHOTOLUMINESCENCE; PREDICTION; RESPIRATORY FAILURE; SEPTIC SHOCK;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BACTEREMIA; FEVER; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTERLEUKIN-8; MIDDLE AGED; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 27644475279     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-005-5068-2     Document Type: Article

References (17)

1. Kern WV: Risk assessment and risk-based therapeutic strategies in febrile neutropenia. Curr Opin Infect Dis 2000; 14: 415-422.
2. Klastersky J: Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004; 39 (Suppl. 1): S32-37.
3. Kern WV: Current epidemiology of infections in neutropenic cancer patients. In: Rolston KVI, Rubenstein EB (eds): Febrile neutropenia. Martin Dunitz Ltd., London 2001, pp 57-90.
4. Elting LS, Rubenstein EB, Rolston KV, Bodey GP: Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 247-259.
5. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Salar A, Peris J, Granena A, Gudiol F: Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis 1999; 18: 539-544.
6. Aledo A, Heller G, Ren L, Gardner S, Dunkel I, McKay SW, Flombaum C, Brown AE: Septicemia and septic shock in pediatric patients: 140 consecutive cases on a pediatric hematology-oncology service. J Pediatr Hematol Oncol 1998; 20: 215-221.
7. Santolaya ME, Alvarez AM, Aviles CL, Becker A, Cofre J, Enriquez N, O'Ryan M, Paya E, Salgado C, Silva P, Tordecilla J, Varas M, Villarroel M, Viviani T, Zubieta M: Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer,fever, and neutropenia. Clin Infect Dis 2002; 35: 678-683.
8. Oude Nijhuis CS, Daenen SM, Vellenga E, van der Graaf WT, Gietema JA, Groen HJ, Kamps WA, de Bont ES: Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies. Crit Rev Oncol Hematol 2002; 44: 163-174.
9. Kern WV, Heiss M, Steinbach G: Prediction of gram-negative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis 2001; 32: 832-835.
10. de Bont ESJM, Vellenga E, Swaanenburg JC, Fidler V, Visser-van Brummen PJ, Kamps WA: Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol 1999; 107: 375-380.
11. Fleischhack G, Kambeck I, Cipic D, Hasan C, Bode U: Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol 2000; 111: 1093-1102.
12. Engel A, Steinbach G, Kern P, Kern WV: Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis 1999; 31: 185-189.
13. Ruokonen E, Nousianen T, Pulkki K, Takala J: Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis 1999; 18: 283-285.
14. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, Schmidt-Wolf IG, Marklein G, Schroeder S, Stuber F: Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 2004; 23: 539-544.
15. Jimeno A, Garcia-Velasco A, del Val O, Gonzalez-Billalabeitia E, Hernando S, Hernandez R, Sanchez-Munoz A, Lopez-Martin A, Duran I, Robles L, Cortes-Funes H, Paz-Ares L: Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 2004; 100: 2462-2469.
16. Persson L, Engervall P, Magnuson A, Vikerfors T, Soderquist B, Hansson LO, Tidefelt U: Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis 2004; 36: 365-371.
17. Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, Reuter S, von Baum H, Marre R: Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenuc patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24: 111-118.